This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 code | G40.31 |
|---|---|
| Special Copayment Reduction code | V279 |
| Synonyms / related terms | Intractable generalized epilepsy, drug-resistant JME, intractable absence epilepsy, intractable generalized tonic-clonic seizures |
| Classification | Severe intractable disease (Special Copayment Reduction registration criteria: 5 years) |
Generalized idiopathic epilepsy (GIE) has been clinically recognized since the 18th century, but the modern understanding advanced dramatically with the development of electroencephalography (EEG) technology in the 1950s. After Hans Berger first recorded the human EEG in 1929, Lennox and Gibbs elucidated the association between absence seizures and the 3 Hz spike-wave complex, thereby establishing the EEG characteristics of generalized epilepsy.
In the 1950s, Janz described juvenile myoclonic epilepsy (JME) as a clinical syndrome, and childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), and others were subsequently classified as separate syndromes. In the 1989 ILAE classification, generalized idiopathic epilepsy was formally included in the classification system, and in the 2017 revised ILAE classification "idiopathic" was redefined as "genetic" etiology.
G40.31 refers to intractable generalized idiopathic epilepsy, a subtype in which seizures persist despite 2 or more appropriate antiseizure medications. Most GIE responds well to medication, but about 15–30% follow an intractable course.
Generalized idiopathic epilepsy is mainly caused by a genetic (polygenic or monogenic) etiology without structural or metabolic causes. In cases with an intractable course, rare genetic variants not identified by standard testing or dual pathology may be involved.
Dravet syndrome due to SCN1A loss-of-function variants shows various seizure types along with generalized tonic-clonic seizures and is characterized by worsening with sodium channel blockers (carbamazepine, lamotrigine), so early genetic diagnosis is important for clinical decisions. GRIN2A variants are more strongly associated with focal than generalized seizures, but some show a generalized seizure phenotype.
In valproate-refractory JME, GABRA1, GABRG2, and CLCN2 variants are identified, and mechanisms related to such channelopathies affect drug response. Other factors in treatment resistance include reduced adherence due to valproate adverse effects, drug interactions, and fluctuations in blood concentration due to enzyme induction.
Inheritance of generalized idiopathic epilepsy follows single-gene autosomal dominant inheritance (ADGGE) or a complex polygenic inheritance pattern. Many susceptibility loci have been found in family linkage analysis and genome-wide association studies (GWAS), with a structure in which common variants each contribute a small amount of risk.
High-risk single-gene variants include SCN1A (Dravet syndrome), SCN2A, SCN8A, KCNQ2, KCNT1, HCN1, GABRA1, GABRG2, and SLC2A1 (GLUT1 deficiency). Apart from Dravet syndrome, single high-penetrance variants account for only a small number of typical GIE syndromes (CAE, JAE, JME), and most are explained by the summation of polygenic risk.
Whole exome sequencing (WES) or whole genome sequencing (WGS) is recommended for classic valproate-refractory GIE, atypical course, or accompanying developmental arrest. De novo variants are strongly associated with severe phenotypes, and SCN8A, KCNA2, and HCN1 de novo variants in particular cause intractable generalized seizures. Genetic results directly influence the choice of treatment drugs (e.g., sodium channel blockers are contraindicated in Dravet syndrome).
Generalized idiopathic epilepsy accounts for about 15–20% of all epilepsy, and prevalence is estimated at about 50–100 per 100,000 population. The most common subtype is JME (5–10% of all epilepsy), followed by CAE (concentrated in early school age, 5–15 years) and JAE.
The prevalence of intractable GIE (G40.31) is about 15–30% of all GIE, estimated at 10–30 per 100,000 population. About 20–30% of JME is not fully controlled even with long-term valproate or levetiracetam monotherapy, and in these cases combination ASM therapy is needed.
In domestic health insurance claims statistics, tens of thousands of people per year receive treatment for generalized idiopathic epilepsy, and registration for Special Copayment Reduction (V279) reduces the burden of high ASM costs. In women especially, the search for alternative drugs because of valproate's fetal malformation risk sometimes causes an intractable course.
The core pathophysiology of generalized idiopathic epilepsy is abnormal hyperexcitability and synchronization of the thalamocortical resonance circuit. Generation of the 3 Hz spike-wave complex is explained by the interaction between GABA-mediated inhibition of the reticular thalamic nucleus and the depolarization shift of cortical pyramidal cells.
Overactivation of the T-type calcium channel (T-type Ca2+ channel; CACNA1H) amplifies burst firing of reticular thalamic neurons and causes repetitive excitatory input to the cortex. That the therapeutic effect of ethosuximide is based on inhibition of this channel is strong evidence.
Reduced GABA-A receptor function (GABRA1, GABRG2 variants), downregulation of GABA-B receptors, and overactivation of glutamate AMPA/NMDA receptors cause an E/I imbalance. In addition, reduced dopamine D1 receptor density in the frontal-thalamic circuit is associated with impulse control disorder and executive dysfunction in JME. Functional abnormalities of hippocampal-frontal connections also contribute to memory and cognitive complications.
The clinical features of generalized idiopathic epilepsy vary by syndrome, but generalized seizures are the common main symptom. The most common seizure types are generalized tonic-clonic seizures (GTCS), absence seizures, and myoclonic seizures, which occur alone or in combination.
JME is characterized by the triad of myoclonic seizures (arm myoclonic jerks after morning awakening), generalized tonic-clonic seizures, and absence seizures. Increased seizure frequency after awakening and worsening of seizures after sleep deprivation and alcohol consumption are typical. Absence seizures are brief seizures with only a few seconds of loss of consciousness, and in CAE may occur frequently, dozens of times a day or more.
In intractable GIE, despite regular ASM use, GTCS persists at least once a month, or myoclonic jerks before seizures are not controlled by ASMs, limiting daily activities (driving, work at heights). Absence status epilepticus or myoclonic status may rarely occur.
In generalized idiopathic epilepsy, interictal neurological examination findings are mostly normal. However, in JME, an inhibitory control deficit is found on tests of frontal executive function, appearing as increased impulsivity, difficulty concentrating, and reduced sense of time.
Myoclonic seizures immediately after a seizure cause falls through failure of postural correction. Tongue biting, joint dislocation, and head trauma may complicate GTCS. Postictal confusion lasts from several minutes to several hours, and during this period memory encoding is impaired so there is no memory of the seizure.
Signs of adverse effects of long-term valproate treatment — weight gain, tremor, hair loss, liver function abnormalities, polycystic ovaries, and hyperammonemia — are items to monitor. When depression, anxiety disorder, or personality change are comorbid in an intractable course, psychiatric consultation is needed.
In standard EEG (30-minute awake EEG), the key is identification of the generalized spike-wave complex (GSWC). Hyperventilation (3 minutes) is the most effective activation method for inducing absence seizures and GSWC, and photic stimulation is used to screen for photosensitive GIE.
Sleep-deprived EEG has a high diagnostic yield in JME, in which myoclonic seizures are provoked after awakening. 24-hour ambulatory EEG or video-EEG is used to differentiate seizure types and to exclude psychogenic non-epileptic seizures (PNES).
Blood tests (complete blood count, liver and renal function, electrolytes, blood glucose, thyroid function, ASM blood concentrations) are performed at the initial and follow-up visits. Gene panel testing (epilepsy gene panel or WES) is recommended for an atypical course, suspected Dravet syndrome, accompanying developmental arrest, or inappropriate response to sodium channel blockers.
Diagnosis of intractable generalized idiopathic epilepsy (G40.31) requires ① meeting the clinical criteria of a generalized seizure syndrome (age-dependent seizure type, characteristic EEG), ② normal brain MRI (excluding structural etiology), and ③ persistence of seizures despite 2 or more appropriate ASMs (adequate dose, blood concentration within the therapeutic range).
"Drug-resistant epilepsy (DRE)" according to the ILAE 2010 criteria means failure of two appropriately chosen and used ASM treatments (monotherapy or combination). Failure of an ASM unsuited to the seizure type (e.g., carbamazepine in JME) is excluded from the determination of drug resistance.
For Special Copayment Reduction registration, a diagnosis certificate from a neurologist (pediatric neurologist), EEG report, MRI reading, and ASM prescription history are submitted to the Health Insurance Review & Assessment Service. The test results used for diagnosis and the drug prescription history are used in reviewing whether the registration criteria are met.
The first-line drug for JME is valproate, with a seizure remission rate of 70–80%. However, the risk of fetal malformation in women of childbearing age (neural tube defects, cardiac malformations, impaired cognitive development), polycystic ovary syndrome, and weight gain as adverse effects necessitate a search for alternatives. Levetiracetam, lamotrigine (caution for possible worsening of myoclonic seizures), topiramate, and clonazepam are used as alternative or add-on therapy.
First-line treatment of absence seizures is ethosuximide (pure absence without GTCS), valproate (with GTCS), and lamotrigine. In intractable absence, clonazepam, zonisamide, and levetiracetam are used as add-on therapy.
Cenobamate is a new add-on therapy option after failure of multiple ASM treatments, and its indication for generalized tonic-clonic seizures is expanding. The ketogenic diet (KD) is reported to reduce seizures by about 50% in children and some adults with intractable generalized seizures. Vagus nerve stimulation (VNS) and deep brain stimulation (anterior nucleus of the thalamus, DBS) are used as adjunctive treatment for intractable GTCS, and the indication for responsive neurostimulation (RNS) in generalized epilepsy is limited.
Most generalized idiopathic epilepsy responds well to ASMs and has a high long-term remission rate, but some patients require lifelong medication. In JME, the seizure recurrence rate after ASM discontinuation reaches 80–95%, so there is a tendency to recommend lifelong treatment.
In intractable GIE (G40.31), the risk of trauma from persistent GTCS, SUDEP risk (about 10-fold increase compared with the general population), neurocognitive decline, mental health problems, and social and occupational restrictions worsen prognosis. Safety management guidance such as a driving ban and restriction of work at heights or in water is essential.
In intractable GIE, seizure reduction can be sought through new ASMs (cenobamate, vigabatrin, fenfluramine), the ketogenic diet, and neuromodulation in combination. Even if seizures are not completely controlled, merely reducing GTCS frequency to less than once a month significantly improves SUDEP risk and quality of life.
Because it is a disease due to genetic predisposition, primary prevention is difficult. When a family member has GIE, early specialist consultation is recommended when seizures first appear in a child. Prenatal genetic counseling is meaningful in families carrying high-risk genes (SCN1A, GABRA1, etc.).
Minimizing seizure triggers: avoid sleep deprivation, heavy drinking, abrupt ASM discontinuation, and photic stimulation (flashing lights, certain video game patterns). Maintaining a regular sleep-wake cycle and stress management contribute to reducing seizure frequency.
Medication adherence education: in female patients, contraception methods and ASM interactions (enzyme-inducing drugs → reduced contraceptive effect), review of switching from valproate when planning pregnancy, and folic acid supplementation during pregnancy are needed. Regular outpatient follow-up (every 3–6 months) is used for monitoring drug blood concentrations, checking adverse effects, and renewing Special Copayment Reduction.